Cargando…

Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis

BACKGROUND: There is a paucity of knowledge concerning erythrocytes in the aetiology of Multiple Sclerosis (MS) despite their potential to contribute to disease through impaired antioxidant capacity and altered haemorheological features. Several studies have identified an abundance of erythrocyte mi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groen, Kira, Maltby, Vicki E., Lea, Rodney A., Sanders, Katherine A., Fink, J. Lynn, Scott, Rodney J., Tajouri, Lotti, Lechner-Scott, Jeannette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963124/ https://www.ncbi.nlm.nih.gov/pubmed/29783973 http://dx.doi.org/10.1186/s12920-018-0365-7

Ejemplares similares

Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes
por: Groen, Kira, et al.
Publicado: (2020)

Erythrocytes in multiple sclerosis – forgotten contributors to the pathophysiology?
por: Groen, Kira, et al.
Publicado: (2016)

Genome-wide DNA methylation changes in CD19(+) B cells from relapsing-remitting multiple sclerosis patients
por: Maltby, Vicki E., et al.
Publicado: (2018)

Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells
por: Sanders, Katherine A., et al.
Publicado: (2016)

Genome-wide DNA methylation profiling of CD8+ T cells shows a distinct epigenetic signature to CD4+ T cells in multiple sclerosis patients
por: Maltby, Vicki E., et al.
Publicado: (2015)

Letter to the editor: blood processing and sample storage have negligible effects on methylation
por: Groen, Kira, et al.
Publicado: (2018)

Differential methylation at MHC in CD4(+) T cells is associated with multiple sclerosis independently of HLA-DRB1
por: Maltby, Vicki E., et al.
Publicado: (2017)

The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis
por: Lycett, Mitchell J, et al.
Publicado: (2023)

DNA methylation changes in CD4(+) T cells isolated from multiple sclerosis patients on dimethyl fumarate
por: Maltby, Vicki E, et al.
Publicado: (2018)

Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients
por: Maltby, Vicki E., et al.
Publicado: (2020)

Whole-blood methylation signatures are associated with and accurately classify multiple sclerosis disease severity
por: Campagna, Maria Pia, et al.
Publicado: (2022)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosis
por: Campagna, Maria Pia, et al.
Publicado: (2023)

A comparison between the pathophysiology of multiple sclerosis and normal pressure hydrocephalus: is pulse wave encephalopathy a component of MS?
por: Bateman, Grant A., et al.
Publicado: (2016)

Epigenome-wide association studies: current knowledge, strategies and recommendations
por: Campagna, Maria Pia, et al.
Publicado: (2021)

Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis
por: Maltby, Vicki, et al.
Publicado: (2023)

Capturing SNP Association across the NK Receptor and HLA Gene Regions in Multiple Sclerosis by Targeted Penalised Regression Models
por: Burnard, Sean M., et al.
Publicado: (2021)

2D in-vivo L-COSY spectroscopy identifies neurometabolite alterations in treated multiple sclerosis
por: Quadrelli, Scott, et al.
Publicado: (2019)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
por: Maltby, Vicki E, et al.
Publicado: (2021)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Can a stress management programme reduce stress and improve quality of life in people diagnosed with multiple sclerosis?
por: Agland, Susan, et al.
Publicado: (2018)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Increased DNA methylation of SLFN12 in CD4(+) and CD8(+) T cells from multiple sclerosis patients
por: Rhead, Brooke, et al.
Publicado: (2018)

DNA Methylation Signatures of Multiple Sclerosis Occur Independently of Known Genetic Risk and Are Primarily Attributed to B Cells and Monocytes
por: Xavier, Alexandre, et al.
Publicado: (2023)

Pain and participation in social activities in people with relapsing remitting and progressive multiple sclerosis
por: Jain, Dhruv, et al.
Publicado: (2023)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Advances in the management of relapsing–remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12)
por: Nielsen, A Scott
Publicado: (2015)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: Lesage, E., et al.
Publicado: (2010)

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
por: Daruwalla, Cyrus, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis
por: Sainz de la Maza, Susana, et al.
Publicado: (2023)

Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis
por: Meijboom, Rozanna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a8rng49kdoa6tdi633rodva5k2